| Price | $4.04 |
| Year Range | $1.6 – $30 |
| Market Cap | $6.6M |
| Industry | Drug Manufacturers |
What Is Apimeds Pharmaceuticals’s AI Stock Analysis?
Apimeds Pharmaceuticals’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks Apimeds Pharmaceuticals’s momentum in near-real time.
Apimeds Pharmaceuticals (APUS) has an AltIndex AI Score of 46/100, currently a Hold signal. The AI Score distills Apimeds Pharmaceuticals's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.
Apimeds Pharmaceuticals’s Full AI Analysis
Keep reading AltIndex’s full AI analysis of Apimeds Pharmaceuticals — the fundamental, technical and alternative-data breakdown and the recommendation.
Sign up to read the full analysisWhat’s Driving APUS’s AI Score?
Fundamentals
Net income for the last quarter was $-20M. This is an increase of -42.46% compared to the quarter before it, which is a positive sign of growth. However, compared to the same quarter last year, there is a decrease of 657.76%, which may be a cause for concern. Ebitda for the last quarter was $-6.3M. This is an increase of -81.63% compared to the quarter before it, which is a positive sign of growth. However, compared to the same quarter last year, there is a decrease of 137.93%, which may be a cause for concern.
See Apimeds Pharmaceuticals’s earnings and insider transactions.
Technicals
Today's stock price is $4.04. This is an increase of 152.50% compared to a month ago, indicating a positive short-term trend. However, compared to a year ago, there is a decrease of 78.04%, which could be a cause for long-term concern. The trend is bearish. The current SMA10 is $5.05, which is lower than the previous SMA10 of $5.35. This suggests a potential downward trend in price movement. The RSI is 71, indicating a potentially overbought (bearish) condition.
See the full technical analysis and price prediction.
Alternative data
Apimeds Pharmaceuticals has an estimate of 0 visitors to their webpage, with no meaningful increase or decrese in the last couple of months.
Explore Apimeds Pharmaceuticals’s job postings, web traffic and app downloads.
Sentiment & social
The sentiment for the stock on various stock forums is high, a positive sign. Apimeds Pharmaceuticals has 5,900 followers on their Twitter page. The number of followers is down by -17% in the last couple of months, indicating a loss in interest in the company.
Track Apimeds Pharmaceuticals’s market sentiment.
Frequently Asked Questions: Apimeds Pharmaceuticals AI Stock Analysis
Apimeds Pharmaceuticals's AltIndex AI Score is 46/100, currently a Hold signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.
AltIndex's AI Score model rates Apimeds Pharmaceuticals a Hold (46/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.
The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.
AltIndex generates a complete written AI analysis of Apimeds Pharmaceuticals — company overview, fundamentals, technicals and alternative data, with a recommendation. See the APUS AI Score or sign up to read the full thesis.
